Not finding it? Sign in to also search OpenAlex live.
-
Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study
Michèle Cavo, Francesca Gay, Meral Beksaç, Lucia Pantani, Maria Teresa Petrucci, Meletios Athanasios Dimopoulos, +54 more
388citations -
Efficacy of Daratumumab, Lenalidomide, and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma and Impaired Renal Function from the Phase 3 Maia Study Based on Lenalidomide Starting Dose
Saad Z. Usmani, Shaji Kunnathu Kumar, Torben Plesner, Robert Zygmunt Orlowski, Philippe Moreau, Nizar Jacques Bahlis, +20 more
5citations -
Sustained Improvement in Health-Related Quality of Life in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone: Update of the Phase 3 MAIA Trial
Aurore Perrot, Thierry T.F. Facon, Shaji Kunnathu Kumar, Torben Plesner, Robert Zygmunt Orlowski, Philippe Moreau, +24 more
1citations -
Lenalidomide-rituximab or lenalidomide-rituximab-bendamustine for relapsed/refractory follicular lymphoma: primary and final analysis of the randomized phase II HOVON110/ReBeL study
Marie José Kersten, M Dreyling, Kim Linton, Dana Chitu, Gerben J.C. Zwezerijnen, Sanne H. Tonino, +32 more
0citations -
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial
Thierry T.F. Facon, Shaji Kunnathu Kumar, Torben Plesner, Robert Zygmunt Orlowski, Philippe Moreau, Nizar Jacques Bahlis, +23 more
376citations -
MM-155: Phase 3 MAIA Study: Overall Survival (OS) Results with Daratumumab, Lenalidomide, and Dexamethasone (D-Rd) vs Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (TIE-NDMM)2021 Clinical Lymphoma Myeloma & Leukemia conference-abstract Medicine Multiple Myeloma Research and Treatments
Robert Zygmunt Orlowski, Thierry T.F. Facon, Shaji Kunnathu Kumar, Torben Plesner, Philippe Moreau, Nizar Jacques Bahlis, +23 more
3citations -
Poster: MM-155: Phase 3 MAIA Study: Overall Survival (OS) Results with Daratumumab, Lenalidomide, and Dexamethasone (D-Rd) vs Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (TIE-NDMM)
Robert Zygmunt Orlowski, Thierry T.F. Facon, Shaji Kunnathu Kumar, Torben Plesner, Philippe Moreau, Nizar Jacques Bahlis, +23 more
0citations -
Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 Trial2024 Journal of Clinical Oncology article Medicine Multiple Myeloma Research and Treatments Open access
Elias Karl Mai, Uta Bertsch, Ema Požek, Roland R. Fenk, Britta Besemer, Christine Hanoun, +71 more
80citations -
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma2023 New England Journal of Medicine article Medicine Multiple Myeloma Research and Treatments Open access
Pieter Sonneveld, Meletios Athanasios Dimopoulos, Mario Boccadoro, Hang Quach, P. Joy Ho, Meral Beksaç, +37 more
590citations -
Long-Term Outcome of a Prospective Randomized Trial Comparing Continuous Lenalidomide/Dexamethasone with Lenalidomide/Dexamethasone Induction, MEL140 with Autologous Blood Stem Cell Transplantation and Single Agent Lenalidomide Maintenance in Patients of Age 60-75 Years with Newly Diagnosed Multiple Myeloma
Christian Straka, Kerstin Schaefer‐Eckart, Bernd Hertenstein, Florian C. Bassermann, Hans Jürgen Salwender, Christian H. Langer, +32 more
17citations -
Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy for Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Final Progression-Free Survival Analysis of Part 1 of an Open-Label, Multicenter, Randomized, Phase 3 Trial (GMMG-HD7)
Hartmut Goldschmidt, Uta Bertsch, Ema Požek, Axel Benner, Roland R. Fenk, Britta Besemer, +26 more
1citations -
Plain Language Summary of the MAIA Study of Daratumumab Plus Lenalidomide and Dexamethasone for the Treatment of People with Newly Diagnosed Multiple Myeloma
Thierry T.F. Facon, Shaji Kunnathu Kumar, Torben Plesner, Robert Zygmunt Orlowski, Philippe Moreau, Nizar Jacques Bahlis, +18 more
2citations -
Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Vrd Alone in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Eligible for Autologous Stem Cell Transplantation (ASCT): Primary Results of the Perseus Trial
Pieter Sonneveld, Meletios Athanasios Dimopoulos, Mario Boccadoro, Hang Quach, P. Joy Ho, Meral Beksaç, +37 more
18citations -
Health-Related Quality of Life in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Data from the Perseus Trial of Subcutaneous Daratumumab Combined with Bortezomib, Lenalidomide, and Dexamethasone (D-VRd)
Pieter Sonneveld, Meletios Athanasios Dimopoulos, Mario Boccadoro, Hang Quach, Phoebe Joy Ho, Meral Beksaç, +38 more
1citations -
P957: CARFILZOMIB, LENALIDOMIDE, DEXAMETHASONE FOLLOWED BY A SECOND AUTO-HCT IS AN EFFECTIVE STRATEGY IN FIRST RELAPSE MULTIPLE MYELOMA: A STUDY OF THE CHRONIC MALIGNANCIES WORKING PARTY OF EBMT
Romain Tilmont, Ibrahim Yakoub‐Agha, Diderik-Jan Eikema, Nienke Zinger, Mathias Haenel, Nicolaas PM Schaap, +18 more
1citations -
Impact of Minimal Residual Disease on Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Treated with Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy in the Phase 3 GMMG-HD7 Trial
Hans Jürgen Salwender, Michael Hundemer, Uta Bertsch, Ema Požek, Axel Benner, Roland R. Fenk, +27 more
1citations